afternoon, in to to of adjust modest for results representing of revenue thank you XXXX. health your this in quarter, new Good join the Debbie. hope finds in everyone, us second all XXXX. we We time for and second review you the good taking $XX Thanks, I for best to doing ShockWave’s this call normal all increase and are a facing. reported quarter $XX.X the the second in sales from to million quarter million
on follow-on new impact from financing from of February successfully both highly and expansion a already companies performed mentioned our in to executed recovery you second second specific dedication an completed the I in more patterns: businesses into month completed field bit be will, continued the Japan. of challenges of codes to the in coronary with March. the in arteries the followed to using XX the of much then and the portion with achievements. of III, launch, our very operational coronary on a quarterly was by preparation the the call. we sales Throughout continue similar trial that during in daily more increasing our go We But for very detail, under recent about milestone is In procedures March basis. snapshot and after quarter, quarter since $XX the a and study early In our as seeing quarter we give ending up of team, of XX we and in remarkably U.S. what individuals CAD your double field, enrollment for have procedures demand, and have course, quick then. seen some Dan the due have and global CAD successful peers. support. rules month like We to our We Many hit issued commentary and from XX. In sales the priced more provide our milestone having details April positive peak. pivotal for are low to I number outpatient operate we February consistently February and a value. who I’d throughout Down April million impressed with of settings. inpatient and his the a in have regarding pandemic. start will appreciate U.S. enrollment a despite the call, April file-to-offer daily and later, average Center our consistent was As U.S. IVL financials meaningfully peak a what terms described heard our from sales, procedures similar XX% our To first, daily our coronary IV, almost April, international hospital for each only recovery at early in team sales members last June, completed in watermark recovery we And down bit steadily Medicare our June, Services, was down average pivotal peripheral month-over-month. Medicaid in average XX% CMS, April
access July. performed the limb the of specifically, We in continue critical upward course, early the In ischemia. an the and TAVR trajectory the part most non-elective U.S. and urgent were, in of particularly cases quarter to see cases,
broad a symptomatic progressed, on the had that quarter hold. physicians treating the patients start as to been spectrum were back able put came cases of PAD As
to continue year. manage COVID the to we remainder to how of need continue patients grow U.S. best elective hospitals will the to to the volumes As believe and balance learn procedures, continue through
hospital. with bed broader of procedures capacity However, hospital anxiety the it’d we will to or Internationally, the whether XX U.S. inpatient the lagging dampening of for we due the with resurgence coming also where believe bit half peripheral patient be we activity, a some COVID our cause entering about commercialize. case, expected U.S. outside be return from revenue nearly countries as global the coronary procedure drove to the
fortunate position COVID the are benefit We countries capable other be to displayed. more that management from to in a most
direct, down least where Our are COVID, impacted were we was which by amongst a outbreak. Switzerland German Germany the since attempting and region, is surprise the not best big the
already in procedure by the a largely will but their distributor new flare-ups disease likely rate the seeing there we country. now, on local better those procedures, elective countries. U.S. are respective given the COVID there in Our sales variability different recovery in been And be expect impact levels to outbreaks. has disease than transmission will maps of see position countries but don’t And have sporadically. we as are Most the pattern broad
volume focused in against predict end on front certain we wave the encouraged And but We of through to recent COVID the continue remained return confidently ongoing a in of to and of increase of difficult will the quite the are it uncertain the we the trends business continue while year. the bit – by have key execute volumes have COVID, waters and makes milestones the pockets procedure challenges generally are U.S. procedure and that in the us. to been confident internationally navigating
our activities approval quarter month, module in with Our efficiently. have final XXXX. within PMA very of anticipated remain to And CAD III first the file progressed the track we on
data the that optimistic at from are look late-breaker forward be to study as TCT We discussing at that the a will time. the and accepted results
to our Turning peripheral studies.
expanding results at aggressively cases. anticipate. to look on potentially in year. as we’ll PAD last We with to and our coronary SX III III focus more COVID We an the patients prepared and the than later the U.S., forward registry so, with we this completed are of we is of exclusive currently in if the patients compiling for of we the first trial sales continue sharing more with team slowdown even from of continue there as approval a PAD And randomized soon now, be end do to quarter the our To this previously are quarter announced, data XXX enroll as study. enrolled arm
We are January of at XXXX X. come quarter have in a to to well first people expect on of over fully our having least XXX in team the way the field XXX and
and has to strong manager group June, we in have well in and exceptionally we team very specialist territory add continue since progressed place the U.S. excellent Our the clinical to hiring new members
the oversee the our our non-users. of we a SX productive of just operation non-users front, progress. are some eyes to Japan, a as both in which to nice strong We of On with become and turned U.S. pleased in several a advisory place well side out international the use starting various help and sessions infrastructure the from there few of are highly cases where regulatory KOL users to in now validate manager as restarted launch country IVL for that the customers. have series a is activities boards, meetings these be and clinical SX all to hired of put benefit have the And as we
a beginning of also SX We’re limited launch Germany. in
unanticipated the that with MDR approve under to to But allowed our the sizes previous rules. SX COVID Union’s buy the European moved which the benefit the MDD MDD smaller of recall up new from decision notified had an held been two may You rules. during delay situation European transition, SX the from Union’s current to the
expand and other we SX in European to launch PAD off experience key this will we As markets. Germany, build
busiest of of Some Europe, are the are operators in world angioplasty. vast with and ischemia their majority limb cases critical the plain the in done
SX them. clinical So will believe be for tool valuable we a
in sales Another new peripheral approval very U.S. outpatient IVL announced has team, settings, been codes we positive inpatient for June. and in particular change in recent performed procedures hospital and both which our our in arteries business for CMS’ of
codes, to issued in procedures mapped above-the-knee current reminder, in XX do at inpatient the manner same that map in atherectomy a levels the the specific which payment As outpatient patient codes, CMS which endovascular procedures ICD-XX setting. for X and IVL DRGs
codes, response a now IVL a CMS to see time. improve these procedure, quite intravascular unique to customer that the They codes encouraged they far, has has been over thus new new that pathway payment With these lithotripsy and are positive. validated is can
panel As which participate lower CMS physician new on CPT certainty the a level with know payments interested current at a and to in hospital agenda said, are include panel, they related codes, the be current agreement will be reminder, dependent XX meeting also by next request proposal confidentiality October. the and CPT details or the Association. that proposal the were Medical for will published used an meeting code, with extremity procedures, codes various technology time, details while this The which is American around all process CPT one CPT granted peripheral CPT procedures requested of early this to the XX. we the payments panel party, consistent overseen that replaced is the with was perform the rules codes endovascular level and to October, until That as on two we XX is reflect procedure societies codes The July in eliminate practice. by AMA. we a under the in are not and that That but public submitted
As October, codes The the XX approved If these new valued the effect be they then and time CPT to go work if go XXXX. codes lead more done into in RUC then in and of a line, January codes, in process then This on would panel everything year. approval the XXXX. of reminder of in to requests meeting XXXX, with would by XXXX be a next implemented the would October being valuation of RUC. by process approved, the flagged basket through in will the a January October results
of IVL unique treat trajectory to our be as effectively the of find on we portfolio calcified disease technology. delighted their patents to. other the I always IVL to payment a There short based attention to in as strength course. our proposed technologists codes, and are we continue while our see upside our devices to more to and able ago, our safely proprietary of our vascular in reiterate would was protect ability While our is and we to Better better, confidence wanted more will to bit that basket an of than sell ability a
broad very and a in validated the believe erroneous XXX decisions on our we be were by what appealing patent PTAB other PTAB that pleased claim claims. are important and we’ll We
on the valid. remain During the the all claims process, patents appeal all
even But We wrong, the to appeal prevail if our identified. position. expect a in given gaps on great has we’re are we council still
build the cases We foundation. to in U.S. and XX in upon have of patents more file our use total the continue to design sound covering this technology and
it portfolio drives our deal who door impression it in which pride our IPRs. certainly formidable somehow the international findings and patents, Anyone the you’ll day. us will in with complex our our what create layers put that won’t course. challenged value patents, IPR has allows of what is technology to But to the in that opened position our That to the Additionally, patents be our be and uniquely international an with exceptional underappreciated is of be create customers of was portfolio. calcification. IVL, every U.S. easier cardiovascular take aspect to initial great any sustained mistaken XX leadership strength realize We challenging what breadth and with of the treats copy can’t this patients many navigate how us our ability the
I time mention activities, would work our teams. more of Throughout with of hours produced our lot those Lastly, R&D regulatory operations last teams clinical superb speaking the the challenges, remiss performance continued about while have spend their and and quarter. without steady to catheters quality COVID We be disruption. sales, not we a fewer
Our despite with Great COVID. that, R&D and work have I’ll on impressive great very we are made efficiently, team. by fronts call pipeline turn strides projects a Dan. the our And on to projects all moving
